Navigation Links
ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation
Date:3/14/2010

ndards of medical care in diabetes-2008. Diabetes Care 2008; 31(suppl 1): S12-S54. [Updated 2009: Executive Summary: Standards of Medical Care in Diabetes-2009. Diabetes Care 2009;32 (suppl 1):S6-S12.]

5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002;106:3143-421.

6. Keech A, Simes RJ, Barter P et al. The FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.

7. Ansquer JC, Foucher C, Rattier S et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DIAS). Am J Kidney Dis 2005;45: 485-93.

8. International Diabe
'/>"/>

SOURCE Residual Risk Reduction initiative (R3i)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
2. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
3. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
4. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
7. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
8. As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
9. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
10. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
11. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 Launched by the ... in December 2011, ,SARAH, - the French ... versus sorafenib in advanced hepatocellular carcinoma (HCC) has enrolled ... SARAH, a large French study of patients ... HCC) has completed patient enrolment, exceeding its 400-patient target, ...
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Halozyme Therapeutics, ... the Barclays 2015 Global Healthcare Conference in Miami, ... ET/10:05 a.m. PT. David A. Ramsay , Chief Financial ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... of the "Gene Therapy Market, 2015 - 2025" ... "Gene Therapy Market, 2015-2025" report provides an extensive study ... of research has been carried out in this field ... approved therapies (four available in Asian markets; one approved ...
(Date:3/3/2015)... March 03, 2015 BlueInGreen ... to their international sales network. The business venture ... technology to Canada’s Atlantic Provinces, exclusively through Resource ... as one of Canada’s premiere manufacturing representative firms, ... the municipal water and wastewater markets. More information ...
Breaking Biology Technology:Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2
... Company to Make Key Marketing Claims, HARBIN, ... Inc. (the "Company") (OTC Bulletin Board: CKGT), a,vertically ... of cactus-based consumer products in China, announced today ... the Company,s Cactus,Cattle Feed. The studies, which included ...
... after an individual becomes infected with HIV the virus ... central nervous system [CNS]). Although this causes no immediate ... dementia and encephalitis (acute inflammation of the brain that ... HIV (SIV) also sometimes develop CNS damage and provide ...
... SAN FRANCISCO, Calif., June 3 Sunesis,Pharmaceuticals, Inc. ... of its,late-stage development leadership team with the appointment ... Vice President, Research and,Development and Mary G. Bolton, ... Judith A. Fox, Ph.D., has been promoted to ...
Cached Biology Technology:China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Company's Cactus Cattle Feed 2China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Company's Cactus Cattle Feed 3Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595) 2Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595) 3Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595) 4Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595) 5Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595) 6
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ... A Global Market Overview" report to their offering. ... to ensure that an individual is who she/he is claiming ... use of a person,s unique physical characteristics, such as fingerprint, ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
(Date:1/22/2015)... Technology Showcase, Hall E -   EyeLock Inc. , ... it will showcase its EyeLock ID technology integrated in a ... Energy,s Oak Ridge National Laboratory (ORNL) at the ... identity authentication technology is being used to validate the driver ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... won the "Most Creative Visualization" award in the "commercial" ... achievement we are extremely proud of. iDEA is Illumina,s ... new and creative visualization and data analysis techniques. ... very first moment we heard about it. Genomatix is ...
... Kan. -- Preliminary research at Kansas State University may make ... scientists believe that cellulose, the most common organic compound on ... biofuels -- if a procedure to effectively break it down ... gives plants their rigidity. Kathrin Schrick, assistant professor in ...
... This press release is available in Spanish ... waters of the European Atlantic Ocean and, nevertheless, resists stock ... the mistakes made by humans. Ms Nerea Goikoetxea, a researcher ... the population dynamics of the northern European hake population, observing ...
Cached Biology News:Learning secrets of world's most common organic compound driving research for biofuels 2Hake population has withstood overfishing, thanks to the warming of the sea 2Hake population has withstood overfishing, thanks to the warming of the sea 3
... portable, easy-to-use and makes identifying your samples more ... to use Labels withstand extreme lab ... Time/Date stamp Laboratory symbols ... Serialization feature makes you more efficient ...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
recombination at attR1 and attR2 sites...
Biology Products: